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Abstract 
The etiology of Idiopathic Environmental Intolerance attributed to Electromagnetic Fields 
(IEI-EMF) is controversial. While the majority of studies have indicated that there is no 
relationship between EMF exposure and the symptoms reported by IEI-EMF sufferers, 
concerns about methodological issues have been raised. Addressing these concerns, the 
present experiment was designed as a series of individual case studies to determine whether 
there is a relationship between RF-EMF exposure and an IEI-EMF individual’s self-reported 
symptoms. Three participants aged 44-64 were tested during a series of sham and active 
exposure trials (2 open-label trials; 12 randomized, double-blind, counterbalanced trials), 
where symptom severity and exposure detection were scored using 100mm visual analogue 
scales. The RF-EMF exposure was a 902-928 MHz spread spectrum digitally modulated 
signal with an average radiated power output of 1 W (incident power density at the 
participant 0.3 W/m2). In the double-blind trials, no significant difference in symptom 
severity or exposure detection was found for any of the participants between the two 
conditions. Belief of exposure strongly predicted symptom severity score for all participants. 
Despite accounting for several possible limitations, the present experiment failed to show a 
relationship between RF-EMF exposure and an IEI-EMF individual’s symptoms. 
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Introduction 
A small proportion of the population report experiencing a wide range of non-specific 
symptoms which they attribute to the electromagnetic fields (EMF) emitted by various 
electronic and wireless technologies. Commonly referred to as Electromagnetic 
Hypersensitivity (EHS), the condition is characterized by a variety of dermatological, 
neurasthenic and/or vegetative symptoms, with headaches, nausea, skin irritations, fatigue 
and concentration difficulties amongst the most commonly reported symptoms [Hagström et 
al., 2013; Hillert et al., 2002; Kato and Johansson, 2012; Röösli et al., 2004]. Generally, the 
reported symptoms are claimed to be triggered by technologies which emit EMF in the 
radiofrequency (RF-EMF) and extremely low frequency (ELF-EMF) domains of the non-
ionizing radiation spectrum, at levels well below the thresholds known to cause adverse 
health effects in humans [ICNIRP, 1998; ICNIRP, 2010]. These devices include mobile 
phones and their base-stations, Wi-Fi, electricity transmission and distribution systems, and 
‘smart’ meters. The condition can have major implications for an individual’s quality of life 
and is often associated with decrements in general health status, increased levels of distress, 
increased levels of health service use and serious impairments in occupational and social 
functioning [Johansson et al., 2010]. 
Yet, despite the considerable prevalence of the condition globally (estimated to be between 
1.5 – 13.5%) [Baliatsas et al., 2015; Blettner et al., 2009; Eltiti et al., 2007b; Hillert et al., 
2002; Levallois et al., 2002; Schreier et al., 2006; Schröttner and Leitgeb, 2008; Tseng et al., 
2011], recent reviews of the scientific literature have concluded that there is no relationship 
between exposure to EMF and the non-specific symptoms reported by EHS individuals 
[Health Canada, 2015; Health Council of the Netherlands, 2009; Röösli et al., 2010; Rubin et 
al., 2005; Rubin et al., 2010; SCENIHR (Scientific Committee on Emerging and Newly 
Idenified Health Risks), 2015]. This discrepancy between the scientific consensus and the 
subjective reports of sensitivity to EMF not only limits the treatment options and support for 
those who experience EHS, but also leaves some members of the public feeling uncertain and 
anxious about potential adverse health effects of EMF exposure. Due to the lack of evidence 
for an association between exposure to EMF and EHS, the World Health Organization 
recommended that the term Idiopathic Environmental Intolerance attributed to 
Electromagnetic Fields (IEI-EMF) be used in place of EHS to avoid implying a causal role of 
EMF in producing the reported symptoms [World Health Organisation, 2004]. 
Experimental provocation studies have been predominately used as a means of investigating 
IEI-EMF. In these studies, a participant is exposed to both active and sham EMF under 
controlled, preferably double-blinded protocols, while their symptomatic response to each 
condition is monitored. Over the past decade, a number of provocation studies using a range 
of EMF and varying methodologies have failed to provide sufficient evidence to support the 
view that IEI-EMF is directly associated with exposure to EMF [Rubin et al., 2010; 
SCENIHR (Scientific Committee on Emerging and Newly Idenified Health Risks), 2015; 
World Health Organisation, 2014]. Indeed, sham exposures alone have been found to be 
sufficient to trigger symptoms in IEI-EMF participants [Nam et al., 2009; Oftedal et al., 
2007; Wilén et al., 2006]. Two studies have also reported an increase in symptoms in an 
initial non-blinded active exposure condition, compared to sham, but have then found no 
significant differences between active and sham conditions in subsequent double-blind trials 
[Eltiti et al., 2007a; Wallace et al., 2012]. Similarly, a recent study reported that IEI-EMF 
participants were unable to correctly identify when they were being exposed under double-
blind conditions, despite an initial verification that they could detect active from sham 
conditions in an open-label trial [van Moorselaar et al., 2017]. These findings have led many 
to suggest that IEI-EMF may be the result of a nocebo response, where conscious or 
subconscious symptom expectation following a perceived exposure to EMF leads to the 
formation or detection of symptoms [Hillert et al., 2008; Landgrebe et al., 2008b; Oftedal et 
al., 2007; Rubin et al., 2010]. Recent findings from a qualitative study, however, suggest that 
instead of the condition originating from a nocebo response, IEI-EMF individuals may be 
using the notion of sensitivity to EMF to provide a narrative to explain their medically 
unexplained symptoms (MUS) in an effort to make their condition more practically and 
emotionally manageable [Dieudonné, 2016].  
Although the reviews cited above have failed to support the view that EMF exposure was 
related to symptoms in self-diagnosed IEI-EMF participants, it is important to note that there 
are a number of studies that have claimed to identify such relations, and which are often used 
in support of the claim that there is a causal relation. However, such studies do not provide 
the claimed support, but are more easily explicable in terms of methodological 
considerations. For example, McCarty et al. [2011] claimed an effect of on-off electric field 
transitions, but as the study was later criticized for lacking clear methodology, and given that 
it has not been replicated, this cannot be taken as evidence for a relation [Rubin et al., 2011; 
Rubin et al., 2012]. Similarly, Kwon et al.[2008] reported that two healthy participants were 
able to detect EMF at greater than chance levels, but they could not replicate their results in 
the same individuals a month later, which suggests that whatever caused the initial significant 
results, it is unlikely that it was due to a bioelectromagnetic phenomenon.  
In line with the focus on methodology, both advocacy groups and some researchers have 
argued that the null results are due to methodological limitations, such as a failure to account 
for the heterogeneous nature of the condition and the way in which participants have been 
selected and tested. For example, it is possible that the samples tested have included a 
combination of both individuals who are sensitive to EMF and others who may suffer from 
unrelated conditions [Rubin et al., 2010]. This is problematic, as the majority of studies have 
taken a nomothetic approach to testing IEI-EMF, and have therefore relied on group means 
which may have had potentially reduced statistical power due to the noise added to the 
analysis from non-responders. In addition, few studies have tested whether the exposure 
signal used was relevant in eliciting symptoms for each individual in the sample, which again 
may have potentially made the RF-EMF exposure irrelevant for many of the participants. 
Furthermore, while the experience of IEI-EMF is known to vary considerably between 
individuals in terms of the type and severity of symptoms experienced and the amount of 
time required for symptoms to develop and subside following exposure [Hocking, 1998; 
Röösli et al., 2004], the majority of provocation studies have not taken this heterogeneity into 
account. Instead, studies have generally used relatively standard exposure and wash-out 
periods across all participants, which, without verification of an open-label effect using the 
particular study protocol, may again make the protocol irrelevant to the reported EMF-
symptom relation and make interpretation problematic. 
Concerns have also been raised about whether the testing environments of provocation 
studies adequately reflect the conditions in which IEI-EMF individuals report symptoms. It is 
possible, for instance, that the laboratory setting has caused some participants to experience 
anxiety, which may have then affected their symptom response. It is also possible, on the 
assumption that there is a relation between EMF and symptoms, that participants have 
encountered other EMF exposures on the way to an experimental session which have then 
inadvertently triggered symptoms [Rubin et al., 2010]. If symptoms had been triggered by 
external factors prior to the experimental manipulation, this would also increase the error 
variance and potentially mask any real effects. However, although it is logically possible that 
these limitations have masked real effects of EMF on symptoms, it is important to point out 
that there is no substantiated evidence that this is the case; such issues need to be determined 
empirically. 
In light of this, the present experiment was designed as a series of individual case studies to 
determine whether there is a relationship between RF-EMF and an IEI-EMF individual’s self-
reported symptoms, employing several important methodological improvements in order to 
overcome potential limitations of previous studies. First, the study utilized a portable 
exposure device which enabled double-blind testing to take place in environments where 
participants generally felt safe and asymptomatic, such as in their own home. This was 
implemented in order to reduce the stress and anxiety which may be experienced by a 
participant in a laboratory setting, while also reducing potential confounding effects 
associated with inadvertent exposures to environmental EMF emissions on the way to an 
institutional testing location. Second, the methodology incorporated a consideration of each 
participant’s IEI-EMF symptom history. This included using a similar RF-EMF exposure to 
the one which the participant claimed triggers symptoms, and both the exposure source and 
reported symptoms were individually verified in an initial open-label, non-blinded trial. This 
limits potential ‘non-responder’ data from statistically confounding ‘responder’ data.  Further 
to this, the study included a consideration of the reported symptom onset and recovery 
periods, such that the testing regime, if necessary, could be modified to incorporate these. A 
sufficient number of sham and exposure conditions were also used to determine statistically, 
within the individual, whether any symptom/exposure relation was significant. Finally, the 
design incorporated a fully counter-balanced protocol in order to reduce time of day and time 
on task effects.  The aim of the study was first to test whether exposure to RF-EMF from the 
portable exposure device resulted in an increase in an IEI-EMF participant’s nominated 
symptom compared to sham, and second, to determine whether IEI-EMF participants could 
detect the active RF-EMF signal at greater than chance levels, under double-blind conditions. 
Materials and Methods 
Participants  
In total, twenty-five potential participants contacted the research center during the 
recruitment period. Of these, three participants aged 44-64 (two male) completed the study. 
Six participants were excluded from the study in an initial phone screen due to not meeting 
the eligibility criteria. The remaining sixteen participants either expressed that they did not 
want to continue participation in the study (after receiving a participant information sheet and 
speaking with the researchers via telephone) or could not be re-contacted by the researchers. 
Participants were recruited through advertisements on the research center website and via a 
press release in the local newspaper and television network. All participants were first 
screened via a telephone interview to confirm eligibility for the study. To be included in the 
study, participants must have reported one or more acute symptoms which they attributed to 
the use of or to their personal proximity to mobile phone or Wi-Fi devices. Acute symptoms 
were defined as any symptom with an onset time of less than 30 min and which took less than 
2 h to subside following exposure, and that could be self-managed without the need of a 
health professional. Participants must have also self-diagnosed or labelled themselves as 
having EHS or IEI-EMF for greater than 1 year. Participants were excluded from the study if 
they reported any serious medical or psychological illnesses, or indicated that they used 
recreational illicit drugs.   
A mutually convenient testing time was arranged with suitable participants. The study was 
approved by the Human Research Ethics Committee (University of Wollongong: HE15/160), 
and informed written consent was obtained from all participants. 
Radiofrequency Exposure 
RF exposure was generated using a portable, self-contained, battery-operated device (Two 
Fields Consulting, St Kilda, Australia). The RF device was placed 30 cm from the participant 
(either on the side or to the front depending on what was comfortable for the participant) on a 
hard surface.  The main exposure from the device was a spread spectrum RF signal in the 
902-928 MHz ISM band which was digitally modulated in a similar manner to signals from 
Wi-Fi and 3G and 4G mobile phones. The RF signal was generated by a commercial RF 
modem which emitted a frequency hopping spread spectrum signal with an average radiated 
power output of 1 W  for 30 min, or was completely EMF silent (RF OFF, sham trials). The 
incident RF exposure level from the side of the device facing the participant was measured 
using a calibrated broadband instrument with an uncertainty of ±2.4 dB for a two-sided 
coverage interval and a coverage factor of 2 (Narda EMR 300 meter and Type 9 E-field 
probe, Narda Safety Test Solutions, Hauppauge, NY), and was found to be 0.3 W/m². This 
RF exposure level is below the power density reference level limit of 4.6 W/m² specified for 
the Australian general public (ARPANSA RPS3) and by the ICNIRP (1998).  It is important 
to note that the maximum localized specific absorption rate (SAR) from the exposure device 
used in the present study is less than that which typically results from personal mobile phone 
use (held against the ear in the active taking mode) due to the greater separation distance. 
Conversely, the whole body averaged SAR and localized SAR of the device used in the 
present study is greater than that which normally results from Wi-Fi and mobile phone base 
station signals. The device was fully enclosed in a thermally insulated case and coded inputs 
were used to maintain double-blinding.  The device contained an independent RF monitor to 
check the status of the RF transmitter and each use of the device was logged using internal 
memory. The fields emanating during the RF ON exposure and sham conditions were 
demonstrated to each participant in the open-label trial using a Nardalert S3 broadband 
monitor (Narda Safety Test Solutions, Hauppauge, NY). This monitor was then removed for 
the subsequent double-blind testing.  
Questionnaires 
Demographic and health questionnaire  
Demographic and health screening questionnaires were used to capture data on the age, 
handedness, education level, gender, general medical condition, and caffeine, tobacco, 
alcohol, illicit and medically prescribed substance use of each participant. 
Symptom history questionnaire 
Two open ended questions were used to assess each participant’s symptom history. These 
were “What are the two most immediate EMF symptoms you experience?” and “Do you 
suffer from any debilitating EMF symptoms?” Participants were asked to include information 
on the source perceived to be responsible for triggering the symptoms, the symptom severity, 
the time of onset and the time needed for the symptom to subside, the first time the symptom 
was experienced and any treatment methods used to relieve the symptom. Participants were 
also asked to indicate any other EMF symptoms which they regularly experienced on a 
checkbox list of 11 common IEI-EMF symptoms [Rubin et al., 2006]. 
WHOQOL-BREF 
The WHOQOL-BREF [World Health Organisation, 1998] assesses how disease impairs the 
subjective well-being of a person across a range of domains. The questionnaire comprises 26 
items, which measure quality of life in the following broad domains: physical health, 
psychological health, social relationships, and environment. 
Symptom and Exposure Status Scale (SESS) 
During the provocation trials, participants were asked to indicate symptom severity and 
exposure status via pen and paper 100mm visual analogue scales. Participants were asked 
“how sure are you of the current exposure status right now?” anchored with the terms 
‘Definitely OFF’ and ‘Definitely ON’, and “how strong/unpleasant is your nominated 
symptom right now?” anchored with the terms ‘Barely Detectable’ and ‘Maximum Severity’. 
While a full symptom history was obtained from each participant prior to testing, the 
symptom tested in the double-blind trials was defined as the most immediate symptom 
triggered during the initial open-label RF ON trial.  
Design  
Each participant’s symptom severity and exposure detection ability was tested under a series 
of 14 sham and active provocation trials. On the first day of testing, two open-label trials (1 
RF OFF, 1 RF ON) were conducted, where both the participant and the researcher were 
aware of the exposure status. This was used to determine whether the exposure device could 
trigger individually-relevant symptoms in each participant. If a participant did not report 
symptoms or was unable to detect the exposure in the RF ON condition in this initial test, 
their participation in the experiment ceased at this point. The initial open-label trials were 
followed by a series of 12 double-blind, randomized, counterbalanced trials, consisting of 6 
sham and 6 RF ON exposure conditions. This was achieved using the Excel randomization 
command, such that a sham and RF ON condition were treated as a pair; the conditions of 
each pair were randomly allocated before assigning the next pair; where more than two 
sequential pairs had the same order the third pair was replaced with the alternate pair order; 
and no more than three of the same pair-order were permitted. In total, each trial ran for 105 
min (except for the RF OFF open-label trial, where there was no post-trial assessment or rest 
interval as there had been no exposure). For each participant, the 14 trials took 24 h to 
complete, spread over a period of 3 consecutive days (the number of RF ON and sham trials 
were matched within each day). 
Testing Location 
Testing was conducted in a safe, asymptomatic environment (determined by the participant) 
in order to reduce stress and to reduce any confounding effects due to environmental RF 
emissions. In all three cases, participants chose (and were tested in) their own home.  
Procedure 
Upon arrival at the participant’s home, the researchers set up the exposure device in a 
comfortable area and ensured that all known electronic and RF emitting devices were 
switched off. All participants were then given a verbal description of the ensuing session 
before completing demographic and health screening questionnaires. To begin the 
provocation trials, participants were asked to sit comfortably in a chair with the exposure 
device placed approximately 30 cm from  them (either to the side or in front of them, 
depending on what was comfortable for the participant). The progression of each provocation 
trial is shown in Figure 1. The first day of testing began with  two open-label trials. The first 
open-label trial was an RF OFF (sham) trial, which began with a 15 min baseline interval (no 
exposure; status known to participant and researcher) to assess the participant’s symptom 
severity pre-trial. The SESS was completed at the 1- and 14-min mark (B1 and B2) of the 
trial. This was followed by a 30 min exposure interval, where the exposure device was 
switched to an RF OFF (sham) setting (exposure status known to the participant and 
researcher) and the SESS was again completed at the 16-, 30- and 44-min mark of the trial 
(E1, E2 and E3). The RF OFF open-label trial was immediately followed by the RF ON 
(active) open-label trial. Again, a 15 min baseline interval (no exposure; status known to 
participant and researcher) was used to assess the participant’s symptom severity pre-trial.  
The SESS was completed at the 1- and 14-min mark (B1 and B2) of the trial. This was 
followed by a 30 min exposure interval where the exposure device was switched to an RF ON 
setting (exposure status known to the participant and researcher) and the SESS was 
completed at 16-, 30- and 44-min mark (E1, E2 and E3) of the trial. The exposure interval 
was then followed by a 30-min post-exposure assessment (no exposure; status known to the 
participant and researcher), where the SESS were again completed at the 46-, 60- and 74-min 
mark (PE1, PE2 and PE3) of the trial. The post-exposure interval was followed by a 30 min 
rest interval, where the participant was free to move around, rest and consume food and water 
before the onset of the next trial. The subsequent 12 double-blind trials followed the same 
progression as the open-label RF ON trial, except that during the exposure interval, the 
exposure device was set to either sham or RF ON (status unknown to the participant and 
researcher) depending on randomization and counterbalancing.  
Statistical Analysis 
Statistical analyses were performed with SPSS statistical package 21.0. For each individual, a 
Mann-Whitney U test was used to assess the difference in symptom severity and exposure 
detection ability, comparing the 6 sham to the 6 RF ON double-blind exposure conditions 
(which are treated as independent). This provides power (0.80) to detect effect sizes of > 1.6 
with an alpha = 0.05, which is consistent with the (anecdotal) reports of effect sizes from IEI-
EMF sufferers (who claim to be able to reliably detect and/or suffer symptoms from EMF).  
It is important to note that there are currently no effect sizes related to actual effects of 
exposure, which is why one based on anecdotal reports of IEI-EMF has been used. The 
primary dependent variable was the difference between the baseline score at 14 min of the 
trial (B2) and the exposure score at 44 min of the trial (E3), for both symptom severity and 
exposure detection. A difference score was used to minimize the influence of baseline 
variability and potential carry-over effects. In order to determine the magnitude of the effect 
induced by the open-label exposure for each participant, an effect size was calculated, based 
on the difference in symptom severity for the RF ON and RF OFF condition. However, 
because there is no measure of variability in the open-label trial, the experimental double-
blind data was used to calculate a standard deviation. To achieve this, the effect of belief of 
exposure first needed to be removed. To do this, a simple linear regression was conducted to 
predict symptom score based on how confident each participant was that the exposure was on 
or off in the double-blind trials (belief of exposure), and unstandardized residuals were 
calculated. The unstandardized residuals were then used to calculate the standard deviation, 
which could then be used in the effect size calculation of the open-label trials. These linear 
regressions  also provided important information regarding the potential relation between 
belief and symptom severity for each participant via the resultant r-squared values. 
Results 
General health status 
The participants did not report any severe medical or psychological conditions. One 
participant reported suffering from tinnitus and one participant was on thyroid hormone 
replacement therapy but was clinically euthyroid at the time of the tests. 
Effect size in the open-label trials  
Confiriming that the open-label manipulation had worked in each case, all of the calculated 
effect sizes in the open-label trials were extremely large (P01 = 5.97, P02 = 3.66, P03 = 
6.98), and much larger than the traditionally used nomenclature of Cohen [1988], which 
treats the largest category of effect size as >.5. 
Participant 1 (P01): 
Symptom history 
The two most common immediate symptoms the participant reported experiencing in 
response to EMF were headache (severity 8/10) and dizziness (severity 8/10), with an onset 
time of 10 min and taking up to 2 h to subside. The two most common debilitating symptoms 
reported by the participant were Vertigo (with an onset time of 12 to 24 h following exposure 
and taking up to 2 days to subside), and confusing thoughts (onset time and time needed to 
subside not known). The participant also reported experiencing nausea, fatigue, eye pain, skin 
itching, sensation of burning on the skin, memory loss, insomnia and immune system 
deficiency. These symptoms were attributed to mobile phone base stations, Wi-Fi, mobile 
phones and wireless phones. The symptoms developed 5 years prior to testing. Although the 
participant reported a number of symptoms, headache was reported as the immediate 
symptom in the RF ON open-label trial and used as the symptom assessed in the double-blind 
trials.  
Exposure Detection and Symptom Provocation 
Open-label trial: The results of the open-label trial are shown in Figure 2a. In the RF ON 
condition, the participant was confident that the exposure device was emitting RF, and 
experienced an increase in symptom severity from baseline throughout the trial. As shown in 
Figure 2a, the severity of these symptoms gradually decreased during the post-exposure 
interval.  These results indicate that the participant developed symptoms and reported 
detecting the active RF signal. A gradual decrease in symptom severity post-exposure was 
also observed. The participant did not detect the presence of RF or exhibit an increase in 
symptom severity in the RF OFF condition. 
Double-blind trials: The results of the double-blind trials are shown in Figure 2b. Symptom 
severity (Median =14.00 versus 34.00, U = 15.00, z = -.481, p = .699, r = .139) and detection 
ability (Median = 54.50 versus 86.50, U = 17.50, z = -.087, p = .930, r = .025) did not differ 
significantly between the RF ON and sham trials respectively.  The regression analysis 
showed that ‘belief of exposure’ significantly predicts symptom severity (F(1, 10) = 48.799, 
p < .001; R2 = .830). 
WHOQOL-BREF 
As shown in Table 1, the participant’s overall quality of life, physical health, psychological 
health and overall health scores are below the mean population norm (but within one standard 
deviation). The social relationships and environment scores are above the population norms. 
Participant 2 (P02): 
Symptom history 
The two most common immediate symptoms the participant reported experiencing in 
response to EMF were feelings of ‘induced hangover’ with an onset time of 30 seconds to 5 
min (severity 5/10) and a burning sensation in the throat (severity 5/10) with an onset time of 
4 to 5 min. The participant reported that the time symptoms take to subside can vary 
substantially depending on the exposure, but estimated a range of between 30 min to 4 h. No 
debilitating symptoms were reported by the participant. The participant also reported 
experiencing eye pain and spots on the face. The reported symptoms were attributed to 
mobile phones and developed 16 years prior to testing. Although the participant reported a 
number of symptoms, a burning sensation in the throat was reported as the immediate 
symptom in the RF ON open-label trial and was therefore used as the symptom assessed in 
the double-blind trials. 
Exposure Detection and Symptom Provocation 
Open-label trial: The results of the open-label trial are shown in Figure 2c.  In the RF ON 
condition, the participant was confident that the exposure device was emitting RF, and 
experienced an increase in symptom severity from baseline throughout the trial. The severity 
of this symptom fluctuated during the post-exposure interval.  These results indicate that the 
participant developed an individually relevant symptom and reported the presence of the 
active RF exposure. In the RF OFF trial, the participant did not report the presence of RF but 
a slight increase in symptom severity was also observed. 
Double-blind trials: The results of the double-blind trials are shown in Figure 2d. Symptom 
severity (Median = 6.50 versus 2.50, U = 14.00, z = -.656, p = .512, r = .189) and detection 
ability (Median = 49.00 versus 15.50, U = 8.00, z = -1.601, p = .109, r = .462) did not differ 
significantly between the RF ON and sham trials respectively.  The regression analysis 
showed that ‘belief of exposure’ significantly predicts symptom severity (F(1, 10) = 79.290, 
p < .001; R2 = .888). 
WHOQOL-BREF 
As shown in Table 1, the participant’s overall quality of life score is below the population 
norm, overall health score above the population norm, and the remaining domains are within 
the population norms. 
Participant 3 (P03): 
Symptom history 
The two most common immediate symptoms the participant reported experiencing in 
response to EMF were feelings of pain and strain in the head and ears with an onset time of 1 
to 5 min (severity 5/10), which they attributed to Wi-Fi. The participant reported that these 
symptoms subside within 5 to 15 min. The participant also indicated that they experience 
headache, mild dizziness, fatigue, tinnitus, and “sensations which self-highlight in the knees, 
elbows, tendons and lower arms” which they attributed to EMF exposure. The participant 
also reported experiencing a heavy head and eyelids, memory loss, pain and strain, and a 
tingling sensation attributed to EMF from television, however, the symptomatic response to 
EMF from television was unable to be tested in the current protocol. The reported symptoms 
developed at least 12 years prior to testing.  Although the participant reported a number of 
symptoms, a feeling of pain and strain in the head and ears was reported as the immediate 
symptom in the RF ON open-label trial and was therefore used as the symptom assessed in 
the double-blind trials. 
Exposure Detection and Symptom Provocation 
Open-label trial: The results of the open-label trial are shown in Figure 2e. In the RF ON 
trial, the participant was confident that the exposure device was emitting RF and they 
experienced an increase in symptom severity during the trial. The severity of this symptom 
decreased during the post-exposure interval. In the RF OFF trial, the participant did not report 
the presence of RF but there was a decrease in symptom severity from baseline.  These 
results indicate that the participant developed symptoms and reported detecting the presence 
of RF during the RF ON exposure trial. 
Double-blind trials: The results of the double-blind trials are shown in Figure 2f. Symptom 
severity (Median = 0.50 versus 1, U = 17.50, z = -.082, p = .935, r = .024) and detection 
ability (Median = 50.50 versus 47.00, U = 12.00, z = -.966, p = .334, r = .288) did not differ 
significantly between the RF ON and sham conditions respectively. The regression analysis 
showed that ‘belief of exposure’  significantly predicts symptom severity (F(1, 10) = 34.093, 
p < .001; R2 =.773). 
WHOQOL-BREF 
As shown in Table 1, the participant’s overall quality of life is below the population norm, 
their psychological health, social relationships, physical health and environment scores are 
well below the population norms, and their overall health score is below the population norm 
(but within 1 SD). 
 
 Discussion and Conclusions 
A number of methodological issues have been raised by both IEI-EMF advocacy groups and 
researchers as possible explanations for why provocation studies have generally failed to 
provide evidence of a relationship between EMF exposure and IEI-EMF symptoms.  The 
present study was designed as a series of individual case studies which incorporated several 
methodological improvements to overcome limitations of previous studies. In order to 
determine whether these methodological improvements were adequate in providing the 
necessary conditions to test IEI-EMF participants, an initial open-label trial was conducted in 
each case.  
Crucially, the results of these open-label trials show that the limitations of previous studies 
were sufficiently dealt with. Specifically, the testing environment and the type of exposure 
used were shown to be sufficient to produce the individually relevant symptoms which each 
participant self-nominated as being due to exposure to EMF and for each participant to report 
that RF exposure was indeed active in the RF ON trial. This is important, as it confirms that 
the environment, RF-EMF exposure device and emitting EMF strength used in the study was 
relevant for eliciting symptoms for these particular IEI-EMF individuals. In addition, the 
observed increase in symptoms over the 30 min open-label active exposure interval (on 
average) shows that the exposure interval was sufficient to evoke relevant symptoms in each 
participant, while the reduction in symptoms in the post-exposure interval demonstrates that 
the time course of each trial was sufficient to allow symptoms to subside prior to the next 
trial. The effect sizes observed in the open-label trials in each case were also extremely large 
(greater than 3.6), and much larger than the traditionally used nomenclature of Cohen [1988], 
which treats the largest category of effect size as greater than .5.  These factors verify that the 
protocol used in the present study was appropriate for testing the sample of IEI-EMF 
individuals.  
While all three participants displayed an increased symptom severity and were confident that 
they could detect the presence of RF-EMF in the RF ON exposure condition compared to RF 
OFF in the initial open-label trial, no significant differences in symptom severity or exposure 
detection between the RF ON and sham conditions were found in the double-blind trials. 
These findings correspond to those reported by Eltiti et al. [2007a] and Wallace et al. [2012], 
who found that IEI-EMF participants had a greater symptomatic response in an initial open-
label active trial compared to sham, but no difference in subsequent double-blind trials. 
Likewise, in a study similar to the present investigation, van Moorselaar et al. [2017] reported 
that IEI-EMF participants were unable to correctly identify when they were being exposed 
during double-blind testing, despite participants reacting to the exposure in an initial 
unblinded test.  Generally, the results of the present experiment agree with the majority of 
previous studies, which have not found any relationship between IEI-EMF symptoms and 
EMF exposure in double-blind provocation paradigms [Rubin et al., 2005; Rubin et al., 
2010]. 
Interestingly, belief of exposure was found to significantly predict symptom severity, with 
belief accounting for 83, 89 and 77 percent of the variance for Participants 1, 2 and 3 
respectively.  This may explain why a sham exposure is sufficient to trigger symptoms, as has 
been reported previously [Nam et al., 2009; Oftedal et al., 2007; Wilén et al., 2006]. The 
strength of belief was particularly noteworthy in Participant 3, who reported that the 
experiment was designed with a deception element. As a result the participant reported 
detecting RF exposure in the post-exposure interval of the double-blind trials, despite specific 
instruction from both the participant information sheet and the researchers throughout the 
trial that the RF exposure was switched off during the post-exposure interval.  
Although varied, each participant also scored lower than the general population in terms of 
overall quality of life and other measures of health on the WHO-QOL BREF questionnaire. 
This is consistent with the conclusions of many cross-sectional survey studies [Hagström et 
al., 2013; Johansson et al., 2010; Kato and Johansson, 2012], and highlights that, in addition 
to physical impairment, IEI-EMF can significantly impact daily functioning and quality of 
life. This emphasizes the importance of developing appropriate treatments and support for 
these individuals, but given the strong belief within the IEI-EMF community that EMF is a 
cause of their symptoms, this will remain challenging.  
The results of the present study are limited by a number of factors. First, the results of the 
study cannot be generalized across the entire IEI-EMF population due the relatively small 
sample size. Despite intending to recruit a larger sample, it seems that skepticism of the 
scientific process and of the results of previous studies, as well as warnings about the present 
study from IEI-EMF advocacy groups [Stop Smart Meters Australia, 2015], may have led to 
many IEI-EMF sufferers being persuaded not to participate. Nevertheless, the idiographic 
nature of the study protocol and the 6 RF ON and 6 RF OFF comparisons were designed to 
enable the detection of partial IEI-EMF responses within each individual case separately. 
Second, the exposure device used a simulated RF signal in the 902-928 MHz ISM band 
which, although digitally modulated like Wi-Fi and 3G and 4G signals, would not be 
typically reported as being the associated trigger of symptoms by individuals who experience 
IEI-EMF as it is a signal band reserved for industrial, scientific and medical use. The use of 
simulated signals in provocation studies has been criticized [Panagopoulos et al., 2015], 
however, as all 3 participants responded to the active signal in the initial non-blind trial, this 
does not seem to be an issue. Finally, the present study is unable to comment on individuals 
who report more chronic forms of IEI-EMF, as it was unable to assess individuals who report 
more-prolonged symptoms that some IEI-EMF individuals report to result from the build-up 
of exposure from a variety of EMF sources over time [Hocking, 1998; Röösli et al., 2004]. 
Despite accounting for a number of possible limitations of IEI-EMF provocation studies to 
date, the results of the case studies presented here fail to demonstrate that the symptomatic 
response of self-reported IEI-EMF participants is affected by EMF exposure, nor that they 
can detect the presence of RF-EMF emissions at greater than chance levels. As in other 
studies, our results also support an alternative hypothesis for the etiology of IEI-EMF; that 
the symptoms experienced are the result of a nocebo response. Indeed the size of resultant r-
squared values  shows that symptoms are more closely related to belief than EMF itself. 
Given the increasing prevalence of distressing and debilitating IEI-EMF symptoms in the 
general public, there is a great need to better understand the triggers for eliciting a harmful 
EMF nocebo response. Public messaging on the EMF topic by scientists and health 
administrators are no doubt significant influences [Wiedemann et al., 2014; Wiedemann et 
al., 2013].  A nocebo etiology hypothesis also provides useful direction in developing 
effective treatments for people who experience IEI-EMF, whose only current solutions for 
minimizing symptoms involve exposure reduction strategies or the complete avoidance of all 
perceived exposures of EMF. Often these remedies not only involve considerable financial 
cost, but they can also have major implications for social and occupational functioning. 
Unfortunately, the ongoing debate over the etiology of IEI-EMF continues to limit the 
development of appropriate treatments and support of people who experience IEI-EMF. 
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Table and Figure Captions 
Table 1: WHOQOL-BREF participant domain scores and mean population norms. Mean 
population scores were derived from [World Health Organisation, 1998]. 
Figure 1: Provocation trial design. Each trial begins with a 15 min Baseline (B) interval, 
followed by a 30 min Exposure (E) interval, a 30 min Post-Exposure (PE) interval and a 30 
min Rest interval, with a total trial time of 105 mins. Arrows represent the time points where 
the SESS was administered. 
Figure 2: Mean exposure detection and symptom severity scores across the Baseline (B1 – 
B2), Exposure (E1 – E3) and Post Exposure (PE1 – PE3) intervals for P01, P02 and P03 are 
shown, for the open-label (RF ON and OFF) [left column; a, c, e] and double-blind 
provocation trials (RF ON and sham) [right column;b, d, f] separately. 
 
Domain P01 Domain 
Score 
P02 Domain 
Score 
P03 Domain 
Score 
Population 
Norms (SD) 
Overall Quality of Life 4 3 3 4.3 (0.8) 
Overall Health 2 5 3 3.6 (0.9) 
Physical Health 63 81 88 80.0 (17.1) 
Psychological Health 69 63 38 72.6 (14.2) 
Social Relationships 81 56 0 72.2 (18.5) 
Environment 75 69 94 74.8 (13.7) 
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